ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA Oncological Drugs Advisory Committee Gets New Charter, Georgetown’s Schein Is Chairman

October 13, 1978

In Brief: More Than 1,600 Taking First Oncology Nurse Certification Exam; FCC Discussions Planned

April 4, 1986

In Brief: Baltimore Resigns as Rockefeller President; Perry Named Medical Director At Ellis Fischel

December 13, 1991

House approves $210 million for Dept. of Defense cancer research programs.

June 24, 2005

Professional Societies: Tobacco Industry Should Pay For Research, AACR Says

August 15, 1997

Anti-NCI Forces Fail to Raid $70 Million from Cancer Program

September 26, 1975